Sale!

BRAF Gene BRAF Selective Sequencing of Exon 15 Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The BRAF gene is an important piece of the puzzle in understanding various types of cancer. It encodes a protein called B-Raf, which plays a critical role in regulating cell growth. Mutations in the BRAF gene, particularly in exon 15, are associated with several types of cancer, including melanoma, colorectal cancer, and thyroid cancer. These mutations lead to abnormal cell growth and cancer development.

The BRAF Selective Sequencing of Exon 15 Genetic Test is a specialized diagnostic tool used to identify mutations in exon 15 of the BRAF gene. This test is crucial for patients suspected of having cancers that are known to be associated with BRAF mutations. By identifying the presence of these mutations, healthcare providers can make more informed decisions regarding the patient’s treatment options, as certain therapies are specifically designed to target cancers with BRAF mutations.

The test is available at DNA Labs UAE, a leading facility for genetic testing in the United Arab Emirates. The cost of the BRAF Selective Sequencing of Exon 15 Genetic Test is 4400 AED. This price reflects the specialized nature of the test and the valuable insights it provides for personalized cancer treatment plans. DNA Labs UAE is equipped with state-of-the-art technology and staffed by experts in the field of genetic testing, ensuring accurate and reliable test results for patients and their healthcare providers.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

BRAF Gene BRAF Selective Sequencing of Exon 15 Genetic Test

Test Name: BRAF Gene BRAF Selective Sequencing of Exon 15 Genetic Test

Components: Price: 4400.0 AED

Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery: 3 to 4 Weeks

Method: NGS Technology

Test Type: Cancer

Doctor: Oncologist

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for BRAF Gene BRAF Selective Sequencing of Exon 15 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with BRAF Gene BRAF Selective Sequencing of Exon 15 NGS Genetic DNA Test gene BRAF

Test Details:

The BRAF gene is a gene that encodes for a protein called B-Raf, which is involved in cell signaling pathways. Mutations in the BRAF gene have been associated with various types of cancer, including melanoma, colorectal cancer, and thyroid cancer.

Selective sequencing of exon 15 of the BRAF gene refers to a genetic test that focuses specifically on sequencing the 15th exon of the gene. Exons are the coding regions of genes that contain the instructions for making proteins. By selectively sequencing exon 15, this test aims to identify any specific mutations or variations in that region of the BRAF gene.

Next-generation sequencing (NGS) is a high-throughput DNA sequencing technology that allows for the simultaneous sequencing of multiple genes or regions of interest. In the context of the BRAF gene, NGS can be used to analyze multiple exons or regions of the gene simultaneously, including exon 15.

The purpose of performing a selective sequencing of exon 15 of the BRAF gene using NGS is to identify any mutations or variations in that specific region that may be associated with cancer or other diseases. This information can be useful for diagnosis, prognosis, and treatment decisions for patients with cancer, as specific BRAF mutations can be targeted with certain therapies.

Overall, the BRAF gene BRAF selective sequencing of exon 15 NGS genetic test is a molecular diagnostic tool used to analyze a specific region of the BRAF gene for mutations or variations, with the goal of informing clinical decision-making in the context of cancer management.

Test Name BRAF Gene BRAF selective sequencing of exon 15 Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Cancer
Doctor Oncologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for BRAF Gene BRAF, selective sequencing of exon 15 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with BRAF Gene BRAF, selective sequencing of exon 15 NGS Genetic DNA Test gene BRAF
Test Details

The BRAF gene is a gene that encodes for a protein called B-Raf, which is involved in cell signaling pathways. Mutations in the BRAF gene have been associated with various types of cancer, including melanoma, colorectal cancer, and thyroid cancer.

Selective sequencing of exon 15 of the BRAF gene refers to a genetic test that focuses specifically on sequencing the 15th exon of the gene. Exons are the coding regions of genes that contain the instructions for making proteins. By selectively sequencing exon 15, this test aims to identify any specific mutations or variations in that region of the BRAF gene.

Next-generation sequencing (NGS) is a high-throughput DNA sequencing technology that allows for the simultaneous sequencing of multiple genes or regions of interest. In the context of the BRAF gene, NGS can be used to analyze multiple exons or regions of the gene simultaneously, including exon 15.

The purpose of performing a selective sequencing of exon 15 of the BRAF gene using NGS is to identify any mutations or variations in that specific region that may be associated with cancer or other diseases. This information can be useful for diagnosis, prognosis, and treatment decisions for patients with cancer, as specific BRAF mutations can be targeted with certain therapies.

Overall, the BRAF gene BRAF selective sequencing of exon 15 NGS genetic test is a molecular diagnostic tool used to analyze a specific region of the BRAF gene for mutations or variations, with the goal of informing clinical decision-making in the context of cancer management.